A predictive model utilizing endoscopic ultrasound (EUS) parameters has been developed, demonstrating significant efficacy in predicting pathologic complete response (PCR) in esophageal cancer patients undergoing neoadjuvant immunotherapy combined with chemotherapy. Key predictors identified were treatment regimen, negative biopsy findings, RECIST assessment, EUS responsiveness, and downstaging. The model showed an area under the curve of 0.840 and was validated internally. EUS responder status also emerged as a crucial predictor of overall survival.
Journal Article by Liu QN, Chen YF, Luo GY and Zhang X in Surg Endosc
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.